AddedRisk Factors
We may not realize the anticipated benefits from the pending Amicus Acquisition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The Amicus Acquisition involves the combination of two companies that currently operate as independent companies. While we and Amicus will continue to operate independently until the Amicus Acquisition is consummated, the success of the Amicus Acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our and Amicus’ businesses after closing. We plan on devoting substantial management attention and resources to integrating our and Amicus’ businesses so that we can fully realize the anticipated benefits of the Amicus Acquisition. This integration process may be disruptive to our and Amicus’ businesses, and, if implemented ineffectively, could restrict realization of the expected benefits of the Amicus Acquisition. In addition, the acquired Amicus business, including Galafold and Pombiliti + Opfolda, may not be successful,
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
may require greater resources and investments than originally anticipated or may result in the assumption of unknown or contingent liabilities, which could have an adverse effect on us or our results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Potential difficulties we may encounter following closing include the following:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. The commercial success of ROCTAVIAN will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Although administration of a gene therapy product like ROCTAVIAN is intended to correct an inborn genetic defect for at least several years, if the therapeutic effect of ROCTAVIAN decreases significantly or ceases entirely, it is uncertain whether redosing would be possible or effective. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Additionally, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, ROCTAVIAN. If we do not accurately forecast demand and manufacture ROCTAVIAN in amounts that exceed actual demand, then we may build excess inventory that may need to be written off, or incur an impairment charge with respect to the facility where ROCTAVIAN is manufactured, all of which could adversely affect our operating results.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
As part of the drug development process, we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
•geopolitical and economic instability, such as the instability caused by Russia’s invasion of Ukraine and the conflicts in the Middle East;
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
•generic competition to KUVAN tablets and powder described above in this Risk Factors section or potential generic competition from future competitors;
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
management team, organizational structure, and corporate strategy could cause retention and morale concerns among current employees, and may create operational risks.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
Due to the breadth of the healthcare laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement authorities in enforcing such laws, our business activities
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedRisk Factors
personal data necessary to operate our business. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data to recipients outside Europe for allegedly violating the GDPR’s cross-border data transfer limitations. Additionally, companies that transfer personal data to recipients outside of the EEA and/or UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators individual litigants and activist groups.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RewordedRisk Factors
In particular, applicants for MAs Developers of biosimilars are required to demonstrate through comprehensive comparability studies with by the reference biological medicine that: a) best possible means that their biological medicine is highly similar to the reference medicine, medicine in physicochemical and biological terms, notwithstanding natural variability inherent to all biological medicines; and b) there that any observed differences are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality duly justified with regard to their potential impact on safety and efficacy.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Cybersecurity incidents resulting in the failure of our ERP system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access or unavailability of these systems or those of any third parties in our supply chain or on whom we otherwise depend, have occurred in the past and may affect our ability in the future to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the existence of the 2027 Notes may encourage short selling by market participants because the conversion of the 2027 Notes could be used to satisfy short positions, or anticipated conversion of the 2027 Notes into shares of our common stock could depress the price of our common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The terms of the 2027 Notes require us to offer to repurchase the 2027 Notes in the event of a fundamental change (as defined in the indenture governing the 2027 Notes) and the terms of the 2034 Notes require us to offer to repurchase the 2034 Notes in the event of a change of control (as defined in the indenture governing the 2034 Notes).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Further, the CCPA provides California residents with data privacy rights (including the ability to opt out of the sale of personal data), imposes new operational requirements for covered businesses, and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the 2024 Credit Facility contains, and the indenture governing our 2034 Notes contain, and any future indebtedness that we may incur (including the new senior secured credit facilities expected to be entered into in connection with the Amicus Acquisition) may contain, financial and and/or other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our marketed products have received regulatory approval to be commercially marketed and sold in the U.S., the EU, and certain other countries except ROCTAVIAN, which has received regulatory approval to be commercially marketed in the U.S. and conditional approval to be commercially marketed in the EU. countries.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result, we We have in the past and may in the future announce reductions in our global workforce, which could face lead to employee attrition beyond our intended reductions in force and adverse effects on employee morale, diversion of management attention, and adverse effects to our reputation as an employer, which could in turn make it more difficult for us to hire employees in the future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Changes in funding levels of Disruptions at regulatory authorities and government agencies due to changes in funding levels, government shutdowns, reorganization, reduction in force or statutory, regulatory and policy changes can affect their ability to hire and retain key personnel and carry out their normal functions that support our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
While discussions are still ongoing as part of For example, the legislative process, this proposal may EU pharmaceutical reform will generally result in a decrease in data and market exclusivity for our product candidates in the EU.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. employees, as well as our ability to integrate employees who join us as the result of an acquisition or business combination.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2024, We continue to pursue the corporate strategy we announced our new corporate strategy for in 2024, which is focused on innovation, growth, and value commitment, which includes, among other things, the acceleration or discontinuation of certain programs, the continued expansion of our pipeline, update updates to our commercial organizational model, and cost transformation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Trade restrictions and export regulations, or increases in tariffs and additional taxes, including any retaliatory measures, can could negatively impact demand, increase our supply chain complexity and our manufacturing costs, decrease margins, reduce the competitiveness of our products, or restrict our ability to sell products, provide services or purchase necessary equipment and supplies, any or all of which could have a material and adverse effect on our business, results of operations, or financial condition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we entered into a definitive agreement to acquire Amicus Therapeutics, Inc. (Amicus), a publicly traded, global, biotechnology company for $14.50 per share in an all-cash transaction for a total consideration of approximately $4.8 billion. The pending acquisition is expected to strengthen our commercial portfolio by adding two new therapies for the treatment of Fabry disease and late-onset Pompe disease. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions. We intend to finance the transaction through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we entered into a debt financing commitment letter (the Commitment Letter) and related fee letter with certain lenders, pursuant to which the lenders have committed to provide us with debt financing up to approximately $3.7 billion (the Bridge Commitment) in the form of a 364-day senior secured bridge loan facility (Bridge Facility) for the pending acquisition of Amicus. No amounts had been drawn or were outstanding under the Bridge Commitment as of December 31, 2025. In February 2026, we issued $850.0 million in aggregate principal amount of 5.5% senior unsecured notes due 2034 (the 2034 Notes), and the proceeds from the issuance were deposited into an escrow account that will be used to finance the pending acquisition of Amicus. In connection with the issuance of the 2034 Notes, the Bridge Commitment was reduced from approximately $3.7 billion to $2.8 billion. In place of the Bridge Facility, we also expect to enter into a senior secured term loan facility for approximately $2.8 billion in aggregate principal and a new $600.0 million senior secured revolving credit facility in 2026 that will be executed prior to or concurrently with the closing of the pending Amicus acquisition. See "Financial Condition, Liquidity and Capital Resources" below for additional information.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we announced our plan to pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities. Subsequently in December 2025, we committed to a plan to voluntarily withdraw ROCTAVIAN from the market due to lower than previously anticipated commercial opportunities. In connection with this strategic decision, we recorded approximately $240.0 million of restructuring charges in 2025 comprised of an inventory write-off, impairment of long-lived assets, severance and other costs. See Note 19 to our accompanying Consolidated Financial Statements for additional details.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, we completed the acquisition of Inozyme Pharma, Inc. (Inozyme), a publicly traded clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics. The acquisition is intended to strengthen our enzyme therapies portfolio by adding a late-stage enzyme replacement therapy, BMN 401 (formerly INZ-701), for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency. We accounted for this transaction as an asset acquisition since the lead asset, BMN 401, represents substantially all of the fair value of the gross assets acquired. See Note 20 to our accompanying Consolidated Financial Statements for additional information related to Inozyme acquisition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Net Product Revenues include revenues generated from our commercial products. In the U.S., our commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy program, and ALDURAZYME is marketed worldwide by Sanofi. Outside the U.S., our commercial products are sold to authorized distributors or directly to government purchasers or hospitals, which act as the end users.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Cost of Sales increased in 2025 compared to 2024 primarily due to $119.2 million write-off of ROCTAVIAN inventory as a result of our strategic decision in the fourth quarter of 2025 to voluntarily withdraw ROCTAVIAN from the market. Gross margin decreased in 2025 compared to 2024 primarily due to ROCTAVIAN inventory write-off, partially offset by increased sales volume of higher-margin products within our Enzyme Therapies portfolio.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The increase in G&A expense for 2025 compared to 2024 was primarily due to $118.5 million of restructuring charges related to impairment of long-lived assets as a result of our strategic decision in the fourth quarter of 2025 to voluntarily withdraw ROCTAVIAN from the market, and partially due to incremental administrative costs related to ongoing support of business initiatives during the year. These increases were partially offset by bad debt expense recorded in the fourth quarter of 2024 that did not recur in 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The increase in Other Income (Expense), Net, in 2025 compared to 2024 was primarily due to proceeds from insurance related to damaged goods.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, in connection with the pending acquisition of Amicus, we entered into the Commitment Letter and related fee letter with certain lenders, pursuant to which the lenders have committed to the Bridge Commitment, to provide us with debt financing in an aggregate principal amount of up to approximately $3.7 billion in the form of the 364-day senior secured Bridge Facility, subject to customary conditions and entry into definitive financing and ancillary documentation as set forth therein. No amounts had been drawn or were outstanding under the Bridge Commitment as of December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In February 2026, we issued $850.0 million in aggregate principal amount of the 2034 Notes, and the proceeds from the issuance were deposited into an escrow account that will be used to finance the pending acquisition of Amicus. In connection with the issuance of the 2034 Notes, the Bridge Commitment was reduced from approximately $3.7 billion to $2.8 billion. In the event that the acquisition is not completed on or prior to December 19, 2026, or upon the occurrence of certain other events, we will be required to redeem all of the 2034 Notes at par and pay any accrued and unpaid interest. In place of the Bridge Facility, we also expect to enter into a senior secured term loan facility for approximately $2.8 billion in aggregate principal and a new $600.0 million senior secured revolving credit facility in 2026 (the New Revolving Facility) that will be executed prior to or concurrently with the closing of the pending Amicus acquisition. Upon entry into the senior secured term loan facility, the remaining Bridge Commitment will be reduced to zero. Under the New Revolving Facility, we may also borrow up to $150 million to pay fees and expenses related to the pending acquisition of Amicus.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We have acquired and continue to acquire intangible assets in connection with business combinations and asset acquisitions. These intangible assets consists primarily of IPR&D for product candidates. Discounted cash flow models are typically used to determine the fair value of acquired intangible assets for the purposes of allocating consideration paid to the net assets in an acquisition. These models require us to make certain judgments, which include:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•developing appropriate probability of success rates for unapproved product candidates considering their stages of development;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
In 2024, we achieved $2.9 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued making important advancements in our product development pipeline. In the first half of 2024, we focused on value creation through working to accelerate growth, optimize efficiencies and drive operational excellence, including progress in executing on key strategic priorities first outlined in January 2024. We also completed a strategic portfolio assessment of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders. In September 2024, we held an Investor Day, during which we provided an overview of our new corporate strategy focused on innovation, growth, and value commitment. Our new strategy includes, among other things, our plans to expand VOXZOGO for the treatment of conditions beyond achondroplasia, our initiatives to drive sustained growth of the Enzyme Therapies portfolio (ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ and VIMIZIM), and our decision to focus on the U.S., Germany and Italy with respect to ROCTAVIAN. See the risk factor, “Our success depends on our ability to manage our growth and execute our corporate strategy.” described in “Risk Factors” in Part I, Item 1A of this Annual Report.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedMD&A
Cost of Sales increased for 2024 compared to 2023 primarily due to higher sales volumes. Gross margin increased compared to 2023 primarily due to lower per unit manufacturing costs of our enzyme products driven by improved yields.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedMD&A
The increase in G&A expense for 2024 compared to 2023 was primarily due to severance and restructuring costs associated with our portfolio strategy review and the associated organizational redesign efforts announced in 2024, and increased bad debt expense during the fourth quarter of 2024.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in Other Expense, Net, in 2024 compared to 2023 was primarily due to the lower foreign currency transaction losses and decreased loss on non-marketable securities.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RemovedMD&A
In the third quarter of 2023, we determined that it is more likely than not that the deferred tax assets related to a future royalty stream will be realized. In making this determination, we analyzed both the consistent historical royalty earnings and the forecast of future royalty earnings and reached the conclusion that it was appropriate to release the valuation allowance reserve.
Read it in 10-K Feb 24, 2025 at sec.govopen_in_new
RewordedMD&A
Our $600.0 million (undiscounted) of total convertible debt as of December 31, 2024 2025 consisting of our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes), will impact our liquidity due to the semi-annual cash interest payments as well as the and repayment of the principal amount, amount in cash at maturity in May 2027 if not converted.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease These increases in S&M expense for 2024 compared to 2023 was primarily due to spend were partially offset by reduced activities related to ROCTAVIAN as we focused on our commercial efforts in the U.S., Germany and Italy to align with our updated ROCTAVIAN strategy. in 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in Interest Expense decreased in 2024 2025 as compared to 2023 was 2024 primarily due to the settlement of 2024 Notes that matured in August 1, 2024 maturity of our convertible debt (the 2024 Notes). 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We In 2025, we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued to grow our commercial business and advance our product candidate pipeline during 2024. pipeline.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We believe cash generated from sales of our commercial products, in addition to our cash, cash equivalents and short-term investments investments, including proceeds from the 2034 Notes and external financings, will be sufficient to satisfy our liquidity requirements for at least the next 12 months. months, including our agreement to acquire Amicus in an all-cash transaction.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We expect Interest Expense to decrease increase over the next 12 months due to financing related to the settlement of our 2024 Notes. pending Amicus acquisition, including the 2034 Notes issued on February 12, 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
With respect to the risks posed by fluctuations of both hedged and unhedged currencies against the USD, see the risk factor “Our international operations pose currency risks, which may adversely affect our operating results and net income” in “Risk Factors” included in Part I, Item 1A of this Annual Report for additional information.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The unfavorable impact of foreign currency exchange rates on USD reported results in 2024 2025 was primarily driven by the weakening of the Argentine Peso Peso, Brazilian Real and Japanese Yen. Mexican Peso, partially offset by strengthening of the Euro.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The Our $600.0 million unsecured revolving credit facility (Revolving Facility) as of December 31, 2025 is intended to finance ongoing working capital needs and for other general corporate purposes. initiatives.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Twelve Months Ended December 31, 2025 2024 2023 2022 2025 vs. 2024 2024 vs. 2023 2023 vs. 2022 Unfavorable impact of foreign currency exchange rates on product sales denominated in currencies other than USD $ (40.7) $ (107.8) $ (100.0) $ (59.0) $67.1 $ (7.8) $ (41.0)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our Provision for income taxes Income Taxes in 2025 and 2024 and 2023 consisted of state, federal and foreign current tax expense which was offset by tax benefits related to stock option exercises, foreign tax credits, and deferred tax benefits from federal orphan drug credits and federal R&D credits.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
It is uncertain whether the United States will enact The U.S. has not enacted legislation to adopt the Pillar Two framework.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
We continuously evaluate the recoverability of costs associated with pre-launch or pre-qualification manufacturing activities, if any, and capitalize the costs incurred related to those activities if we determine that recoverability is highly likely probable and therefore future revenues are expected.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new